A year in the life of the EU-CardioRNA COST action: CA17129 catalysing transcriptomics research in cardiovascular disease

Emma Louise Robinson*, Clarissa Pedrosa da Costa Gomes, Ines Potočnjak, Jan Hellemans, Fay Betsou, David de Gonzalo-Calvo, Monika Stoll, Mehmet Birhan Yilmaz, Bence Ágg, Dimitris Beis, Maria Carmo-Fonseca, Francisco J. Enguita, Soner Dogan, Bilge G. Tuna, Blanche Schroen, Wim Ammerlaan, Gabriela M. Kuster, Irina Carpusca, Thierry Pedrazzini, Costanza EmanueliFabio Martelli, Yvan Devaux, Shubhra Acharya, Parisa Aghagolzadeh, Sebastian Albinsson, Didier Allaer, Andrejaana Andova, Claudio Angione, Jean François Arnal, Serdal Arslan, Mitja Lustrek, Lars Maegdefessel, Monica Marchese, Fabiana Martino, Chiara Mazzanti, Albano Meli, Julia Mester Tonczar, Mora Murri, Loredan Stefan Niculescu, Johannes Backs, Niklas Nielsen, Anne Yael Nossent, Susana Novella, Natalija Novokmet, Timothy O'brien, Claudia Oliveira, Josune Orbe, Francesca Maria Stefanizzi, Amela Jusic, Olga Kofanova, EU-CardioRNA COST Action

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)


The EU-CardioRNA Cooperation in Science and Technology (COST) Action is a European-wide consortium established in 2018 with 31 European country members and four associate member countries to build bridges between translational researchers from academia and industry who conduct research on non-coding RNAs, cardiovascular diseases and similar research areas. EU-CardioRNA comprises four core working groups (WG1-4). In the first year since its launch, EU-CardioRNA met biannually to exchange and discuss recent findings in related fields of scientific research, with scientific sessions broadly divided up according to WG. These meetings are also an opportunity to establish interdisciplinary discussion groups, brainstorm ideas and make plans to apply for joint research grants and conduct other scientific activities, including knowledge transfer. Following its launch in Brussels in 2018, three WG meetings have taken place. The first of these in Lisbon, Portugal, the second in Istanbul, Turkey, and the most recent in Maastricht, The Netherlands. Each meeting includes a scientific session from each WG. This meeting report briefly describes the highlights and key take-home messages from each WG session in this first successful year of the EU-CardioRNA COST Action.

Original languageEnglish
Article number17
JournalNon-coding RNA
Issue number2
Publication statusPublished - 1 May 2020


  • COST action
  • Cardiovascular disease
  • Interdisciplinary
  • Network
  • Non-coding RNA
  • Translational research


Dive into the research topics of 'A year in the life of the EU-CardioRNA COST action: CA17129 catalysing transcriptomics research in cardiovascular disease'. Together they form a unique fingerprint.

Cite this